The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.
Tentative approval: generic Abacavir Sulfate Oral Solution
The Food and Drug Administration, on June 27, 2006, granted tentative approval for Abacavir Sulfate Oral Solution, 20 mg/mL, manufactured by Aurobindo Pharma Limited Inc., of Hyderabad, India.
This is a generic version of the already-approved Ziagen brand of the product manufactured by GlaxoSmithKline .
The application was reviewed under expedited review provisions for the President's Emergency Plan for AIDS Relief (PEPFAR).
"Tentative Approval" means that FDA has concluded that a drug product has met all required quality, safety and efficacy standards, though it may not yet be marketed in the U.S. because of existing patents and/or exclusivity rights. Tentative approval, however, does make the product eligible for consideration for purchase under the PEPFAR program.
Abacavir sulfate is a member of the class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs), which help keep the AIDS virus from reproducing. This antiretroviral drug is intended to be used in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Office of Special Health Issues
Food and Drug Administration